Analysts Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $7.25

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.25.

A number of research analysts recently issued reports on PRQR shares. Oppenheimer started coverage on shares of ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price target for the company. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Finally, Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $1.56 on Thursday. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10. The stock has a market cap of $164.36 million, a P/E ratio of -3.12 and a beta of 0.08. The firm has a 50-day moving average of $1.65 and a 200 day moving average of $1.80.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The company had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $5.19 million. Research analysts expect that ProQR Therapeutics will post -0.57 earnings per share for the current fiscal year.

Institutional Trading of ProQR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Axiom Investment Management LLC bought a new stake in ProQR Therapeutics during the 1st quarter valued at about $53,000. Bank of America Corp DE increased its stake in ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 11,186 shares in the last quarter. Walleye Capital LLC increased its stake in ProQR Therapeutics by 2.7% during the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 15,744 shares in the last quarter. Invesco Ltd. bought a new stake in ProQR Therapeutics during the 4th quarter valued at about $51,000. Finally, XTX Topco Ltd increased its stake in ProQR Therapeutics by 1,057.4% during the 4th quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 107,713 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.